# Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

> **NCT02993237** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 27 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** DRV/COBI FDC placebo tablet
- **DRUG:** D/C/F/TAF FDC placebo tablets

## Key facts

- **NCT ID:** NCT02993237
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-23
- **Primary completion:** 2017-05-25
- **Final completion:** 2017-05-25
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2019-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02993237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02993237, "Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02993237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*